Gastric type sustained release formulation containing pregabalin, polyethylene oxide and polyvinyl alcohol-polyethylene glycol graft copolymer

摘要

PURPOSE: A gastric-retentive sustained release formulation containing pregavalin, polyethyleneoxide, and polyvinylalcohol-polyethylene glycol graft copolymer is provided to control drug release and to improve swelling property and floatability. CONSTITUTION: A gastric-retentive sustained release formulation contains 100 weight parts of pregavalin or pharmaceutically acceptable salt thereof, 25-500 weight parts of polyethyleneoxide as a swelling agent, and 10-200 weight parts of polyvinyl alcohol-polyethylene glycol graft copolymer.